CD4-specific CAR T Cells (CD4 CAR T Cells) for Relapsed/Refractory T Cell Malignancies
Phase of Trial: Phase I
Latest Information Update: 18 Nov 2019
Price : $35 *
At a glance
- Drugs Anti CD4 CAR T cell therapy-iCell Gene Therapeutics (Primary)
- Indications Peripheral T-cell lymphoma; Sezary syndrome
- Focus Adverse reactions; First in man
- Sponsors iCell Gene Therapeutics
- 18 Nov 2019 New source identified and integrated: ClinicalTrials.gov: US National Institutes of Health (NCT04162340).
- 14 Nov 2019 According to an iCell Gene Therapeutics media release, data from this study will be presented at the 61st American Society of Hematology (ASH) Annual Meeting to be held December 7-10, 2019 in Orlando, Florida.
- 06 Nov 2019 Results released in the 61st Annual Meeting and Exposition of the American Society of Hematology.